Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
3 No-Brainer Dividend Stocks to Buy in September
07:30am, Sunday, 08'th Sep 2024
AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem.
5 Relatively Secure And Cheap Dividend Stocks To Invest In -- September 2024
09:00am, Saturday, 07'th Sep 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
08:00am, Saturday, 07'th Sep 2024
Merck & Co., Inc. NYSE: MRK is one of the largest pharmaceutical firms in the world. The firm ranks fourth behind giants like Eli Lilly NYSE: LLY and Novo Nordisk NYSE: NVO, with a market capitalizati
Buy 3 September Dogs Of The Dow; Watch 6
01:00am, Saturday, 07'th Sep 2024
"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors
Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
06:02pm, Friday, 06'th Sep 2024
Merck & Co., Inc. (NYSE:MRK ) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 2:35 PM ET Company Participants Rob Davis - Chairman and CEO Dean Li - President of Merck Resear
Why Did Merck Stock Rise 65%?
10:00am, Friday, 06'th Sep 2024
Merck stock (NYSE: MRK) has gained over 65% in value since early January 2021 – jumping from levels of $70 then to around $115 now – vs. an increase of about 50% for the S&P 500 over this period.
Merck Starts Late-Stage Study on Recently Acquired Ophthalmology Drug
12:26pm, Thursday, 05'th Sep 2024
The clinical study will evaluate MRK's experimental antibody treatment in patients with diabetic macular edema, a major cause of vision loss.
What's Wrong With Merck's Stock?
04:27am, Thursday, 05'th Sep 2024
Merck's business is growing, but the stock's gains have been modest this year. The drug manufacturer remains heavily reliant on Keytruda, which accounts for nearly half of its revenue.
The Smartest Dividend Stocks to Buy With $5,000 Right Now
04:15am, Thursday, 05'th Sep 2024
Venerable Coca-Cola has increased dividends for more than six decades. Merck's lifesaving treatments aren't affected by economic cycles.
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
11:56am, Wednesday, 04'th Sep 2024
MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
04:17pm, Tuesday, 03'rd Sep 2024
Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.
Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.
10:48am, Tuesday, 03'rd Sep 2024
At the highest dose tested, Vaxcyte's shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer's.
2 Dividend Stocks You Can Safely Hold Through a Recession
08:45am, Monday, 02'nd Sep 2024
These two companies sell products that remain in high demand even during recessions. They also have excellent dividend track records -- and one of them is a Dividend King.
Merck's Change To Profit Guidance Provides An Opportunity
06:58am, Sunday, 01'st Sep 2024
Merck's reduced profit guidance is primarily due to recent acquisitions, but the company remains strong with potential for future growth, especially in 2024. Keytruda continues to be a key revenue dri
Merck (MRK) Advances But Underperforms Market: Key Facts
06:45pm, Friday, 30'th Aug 2024
In the most recent trading session, Merck (MRK) closed at $118.45, indicating a +0.84% shift from the previous trading day.
